Merck adds another OK to Keytruda scoreboard; Ardelyx, Kyowa Kirin broadens partnership beyond tenapanor
→ Merck‘s anti-PD-1 blockbuster, Keytruda, is racking up win after win. The newest jewel to the crown for the company is the
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
